How Chinese biotech is graduating from licensing deals to broader partnerships
- Posted on September 26, 2026
- By South China Morning Post
- 0 Views
- 1 min read
In brief
Generating AI summary…
How Chinese biotech is graduating from licensing deals to broader partnerships
InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.
